Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial

By sjmartinez • February 4, 2024

Wainberg ZA, Kang YK, Lee KW, Qin S, Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, Teixeira A, Hitre E, Udrea AA, Cardellino GG, Sanchez RG, Zahlten-Kümeli A, Taylor K, Enzinger PC. Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial. Gastric Cancer. 2024 Feb 3. doi: 10.1007/s10120-024-01466-w. Epub ahead of print. PMID: 38308771.

Tags: Bemarituzumab, Fgfr2b, gastric cancer, Hematology/Oncology, mFOLFOX6, Publications, targeted therapy

Related Posts

Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation

Peters S, Meyer ML, André F, Argilés G, Azizi AA, Banerjee S, Burgers S, Curigliano G, Drago JZ, Fontana E, Garon EB, Klümper N, Le[...]

Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 Study

Modi S, Murthy RK, Chien AJ, Lin NU, McAndrew NP, Specht JM, Zelnak AB, Ramos J, Xie D, Ho J, Inoue JK, Carey LA, Hamilton[...]

Response to Letter to the Editor: ‘NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial’

Macarulla T, Cid RP, Womack MS, Gracian AC, Zervoudakis A, Hatoum H, Chung V, Patel A, Paulson AS, Pant S, O'Reilly EM, Hubner RA, Van[...]